Alpha 2.0
Login Register
» Authors » Konstantinos Kalbakis

Konstantinos Kalbakis

Explore the profile of Konstantinos Kalbakis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 131
Followers 0
Related Specialties
Oncology
General Medicine
Science
Top 10 Co-Authors
Dimitrios Mavroudis
Sofia Agelaki
Lambros Vamvakas
Dimitrios Makrakis
Konstantinos Rounis
Dimitris Mavroudis
Alexia Monastirioti
Chara Papadaki
Stylianos Kakolyris
John Souglakos
Published In
PLoS One
Int J Radiat Oncol Biol Phys
Ann Surg Oncol
Ann Gastroenterol
Melanoma Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter...
Bafaloukos D, Kouzis P, Gouveris P, Boukovinas I, Kalbakis K, Baka S, et al.
Melanoma Res . 2023 Dec; 34(2):152-165. PMID: 38092014
This study primarily aimed to generate real-world evidence (RWE) on the profile and first-line treatment (1LT) patterns of patients with advanced (unresectable Stage III/metastatic) cutaneous melanoma initiated on immuno-oncology (IO)-...
2.
Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study
Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, et al.
PLoS One . 2023 Nov; 18(11):e0294382. PMID: 37943834
[This corrects the article DOI: 10.1371/journal.pone.0252537.].
3.
Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period
Matikas A, Kotsakis A, Perraki M, Hatzidaki D, Kalbakis K, Kontopodis E, et al.
Breast Care (Basel) . 2022 Aug; 17(3):264-271. PMID: 35949417
Introduction: The purpose of this study was to study the efficacy of subsequent treatment lines for metastatic breast cancer (MBC), as well as the association between radiologic objective response rate...
4.
Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study
Rounis K, Makrakis D, Tsigkas A, Georgiou A, Galanakis N, Papadaki C, et al.
Transl Lung Cancer Res . 2021 Sep; 10(8):3538-3549. PMID: 34584855
Background: Cancer cachexia syndrome (CCS) is an adverse prognostic factor in cancer patients undergoing chemotherapy or surgical procedures. We performed a prospective study to investigate the effect of CCS on...
5.
Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study
Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, et al.
PLoS One . 2021 Jun; 16(6):e0252537. PMID: 34061904
Objective: We prospectively recorded clinical and laboratory parameters from patients with metastatic non-small cell lung cancer (NSCLC) treated with 2nd line PD-1/PD-L1 inhibitors in order to address their effect on...
6.
Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy
Papadaki C, Monastirioti A, Rounis K, Makrakis D, Kalbakis K, Nikolaou C, et al.
Cancers (Basel) . 2020 May; 12(5). PMID: 32438598
The expression of microRNA (miR)-21, miR-128, miR-155, and miR-181a involved in DNA damage response (DDR) and tumor responsiveness to platinum was assessed by RT-qPCR in the plasma of patients with...
7.
BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects
Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, et al.
Int J Cancer . 2020 Feb; 147(5):1334-1342. PMID: 32022259
Germline BRCA1 and BRCA2 loss-of-function variants have been linked to increased breast and ovarian cancer risk, with more than 5,000 distinct pathogenic variants being reported worldwide. Among individuals of Greek...
8.
Brain and bone marrow metastases from rectal cancer
Thomopoulou K, Manolakou S, Messaritakis I, Tzardi M, Lagoudaki E, Koutsopoulos A, et al.
Ann Gastroenterol . 2020 Jan; 33(1):95-97. PMID: 31892804
Despite the development of new treatment options based on the molecular characterization of colorectal cancer, 20% of patients present de novo metastatic disease, whereas 30-40% of patients who receive curative...
9.
Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group
Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, et al.
Clin Breast Cancer . 2017 Nov; 18(1):88-94. PMID: 29153775
Background: Triple-negative breast cancer (TNBC) lacks a standard targeted therapeutic strategy and is treated with conventional cytotoxic agents. Because of the sensitivity of TNBC to platinum compounds and the synergistic...
10.
Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group
Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, et al.
Br J Cancer . 2017 Jun; 117(2):164-170. PMID: 28641315
Background: Sequential anthracyclines and taxanes are standard adjuvant chemotherapy for patients with high-risk axillary node-positive breast cancer. We compared a sequential to a concurrent regimen in high-risk node-negative early breast...